Mr. Craig Millian reports

HLS THERAPEUTICS ANNOUNCES CFO DEPARTURE

Tim Hendrickson is stepping down as chief financial officer of HLS Therapeutics Inc. to pursue other interests and John Hanna, currently a director of the company, has been appointed interim CFO. Mr. Hendrickson will remain in his role until Jan. 26, 2024, to support the transition and the company will undertake a search for a permanent CFO in the new year.

"As one of the company's first hires, Tim played an important role in helping HLS build its portfolio, achieve its public listing and manage its ongoing operations," said Craig Millian, chief executive officer of HLS. "On behalf of the team and the board, I'd like to thank him for his contributions and commitment, and I wish him the best in his future pursuits."

Mr. Millian continued: "John's background as a public company CFO along with his experience on our board and his role on the audit committee make him a great fit as interim CFO. I look forward to working more closely with John as we seek to drive top-line growth and margin expansion with the marketed products in our portfolio."

While serving as interim CFO, Mr. Hanna will remain on the HLS board as a non-independent director.

Mr. Hanna is an accomplished leader with more than 25 years of diverse experience, including in the health care industry, as a C-level executive helping companies to drive revenue growth, scale their operations and expand operating profitability. Previously, he served as CFO at Vecima Networks, Inca Networks and eBuyNow and held a variety of senior financial roles with The Westaim Corp. In addition to being a member of HLS's board and the audit committee, Mr. Hanna has also served as a board member for a number of technology companies. He holds a BSc, biology, from University of Victoria, an MBA from the University of British Columbia and is a designated accountant (CPA, CGA).

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.

We seek Safe Harbor.